MBL2 and HIV infectious disease: In light of all this conflicting evidence it would be difficult to recommend the use of MBL plasma levels, MBL2 structural variants and promoter region mutations as a biomarker of HIV infection and for the monitoring of ARV therapy together with viral load and CD4+ T cell lymphocyte counts in the population represented by our study participants.